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Abstract: Cancer is the second highest cause of death in the world after
cardiovascular disease. Despite the success of chemotherapeutic agents many 
patients are left with the unfortunate side effects of these drugs. Cytotoxic 
antibiotics such as anthracyclines and the monoclonal antibody trastuzamab are 
both commonly used in breast cancer and may cause irreversible cardiotoxicity, 
though trastuzumab-induced damage can be reversed upon stopping. Various 
animal studies have shown that cardioprotective drugs such as ACE inhibitors, 
Beta-blockers and statins can reduce pathological processes such as oxidative 
stress as a result of chemotherapy, however their protective role in human is 
currently unknown.  
In this study, 1229 eligible breast cancer patients who received anthracyclines 
and/or trastuzumab as well as the use of cardioprotective agents were 
retrospectively observed to see if they have therapeutical effects in reversing 
myocardial damage. Furthermore, a population-based record-linkage study of 
all breast cancer patients in Tayside, Scotland undergoing adjuvant 
chemotherapy was carried out to audit the incidence of cardiotoxicity in breast 
cancer as well as adherence to guidelines which was never been evaluated 
previously. Results revealed that although the majority of patients had a 
baseline assessment, when they were divided into anthracycline + trastuzumab 
or anthracycline those receiving anthracycline only had suboptimal surveillance 
of cardiac function. Additionally, the latter group was observed to have a higher 
incidence of Left ventricular systolic dysfunction (LVSD) which is thought to be 
due to a lower rate of surveillance.        
4 
The hypothesis of this study was that the use of cardioprotective drugs such as 
ACE inhibitors, Beta blockers and ARBs as well as cholesterol controlling drugs 
such as statins may be able to reverse the cardiac damage caused by cancer 
therapy drugs such as anthracyclines how ever, the results from the overall 
PROTECT-TAYSIDE study were in disagreement with the hypothesis and 
showed that the use of cardioprotective drugs did not reverse anthracycline-
induced cardiac damage.  
5 
1 Chapter 1: Literature review 
1.1 Introduction: Despite vast developments in molecular biology and 
biochemistry, cancer and the mechanisms involved remain partially understood. 
Cancer is the second commonest cause of death worldwide after cardiovascular 
diseases, with mortality rates reported to be as high as 8.2 million in 2012(1). 
Although recent advances in medical and clinical research have turned cancer 
from a fatal illness to a survivable chronic disease in many cases, anti-cancer 
treatments can have a variety of undesirable side effects and often patients 
show different degrees of toxicity. Adult human cardiomyocytes are highly 
specialised and have complex structures that support cell growth. They enter an 
additional step of DNA synthesis which leaves them binucleated thus making 
them display in determined forms such as binucleation and hypertrophy(5). One 
of the most commonly known adverse effects of chemotherapy is cardiotoxicity, 
whereby the cardiomyocytes are damaged due to the action/nature of anti-
cancer drugs that act by killing cancer cells that divide quickly and proteins that 
are expressed in these cells. An example of such a drug class would be 
Anthracyclines (Ant) which are the most widely used group of anti-neoplastic 
drugs in different types of cancer including breast, ovarian, lung, lymphomas 
and leukaemia(1). Their use has effectively improved survival in childhood 
cancers by 75% and breast cancer by 70%(1). As cardiotoxicity is a known side 
effect of cancer therapy, damaged cardiomyocytes lead to impaired function of 





1.1.1 Heart failure epidemiology:  
Heart failure is a complex condition where the heart’s ability to pump blood 
around the body is impaired and it is recognised as a major public health 
problem in the developed countries. The prevalence of heart failure can be 
estimated at 1-2% with an incidence rate of 5-10 people out of 1000 per year in 
the western world(2). According to figures from information services division 
(ISD) Scotland, Mortality rate for all heart diseases was 328 per 100,000 people 
between 2005, and 212 per 100,000 in 2014, a reduction of 35.6% in the last 
ten years(61).  
1.1.2 Prevalence of Heart failure:  
Heart failure is most frequently seen in people over the age 50 and the 
prevalence continues to increase with age. In 2000, the prevalence of heart 
failure in the UK was reported to be 3 per 1000 compared with 9 per 1000 in 
1958 according to UK national data(3). In 2007 Mosterd and Hoes reported the 
prevalence of HF in the US to be 2.2% ranging from 0.7% in individuals 
between 45-54 years old to 8.4% in individuals over the age of 75 in a 
population size of 2042 randomly selected residents(2).This US-based 
population study also indicated that individuals with systolic dysfunction often 
display subclinical symptoms of recognised heart failure(2). 
1.1.3 Incidence of heart failure: 
In two population-based studies the incidence of heart failure was reported to 
have increased from 0.2/1000 person per year to 12.4/1000 person per year in 
individuals of 45-55 years of age, and the second study known as the 
Rotterdam study the incidence increased from 2.5/1000 to 44/1000 person with 




1.2 Heart failure risk factors  
There are several factors that increase one’s risk of developing heart failure, 
with the most common in the western world being Ischaemic Heart Disease 
(IHD). Coronary artery disease is the predominant cause of heart failure and 
has been shown to increase the chance of developing heart failure within 7-8 
years of an episode of myocardial infarction (MI) in up to 36% of patients(2). 
Although hypertension has a smaller association with heart failure than 
myocardial infarction it contributes significantly as it is more common in the 
population(2). Physical inactivity, smoking, obesity, valvular heart disease and 
diabetes are other contributing risk factors for heart failure.  
Although to a lesser extent, there are other risk factors such as drug side effects 
which can lead to cardiac dysfunction(4). Cardiotoxicity is of a particular interest 
which occurs as a side effect of chemotherapy, especially the anthracycline 
class. As cancer survival increases, chemotherapy-induced cardiotoxicity is 
becoming an increasing concern as it can lead to the development of heart 
failure. Advanced heart failure in patients with the disease characteristics above 
have the same prognosis as metastatic breast cancer. In this review 
cardiotoxicity and possible strategies to reverse or inhibit its effect are 
described.  
1.3 Cardiotoxicity 
The National Cancer Institute defined cardiotoxicity as “toxicity that affects the 
heart”. Although a simple description, it is one of the most feared side effects of 
anticancer therapy and therefore a clear understanding of how cardiotoxicity 
occurs and how to best prevent it remains the objective of many studies in this 
area(5). According to Albini et al(6)l, cardiotoxicity is said to occur when there is a 
reduction in left ventricular ejection fraction (LVEF) to less than 55% 




from baseline. Other features associated with heart failure that may occur in 
patients with cardiotoxicity include arrhythmia and tachycardia or both, 
shortness of breath, fatigue dyspnea and lower limb oedema(6).  
1.4 Epidemiology of cardiotoxicity related heart failure: 
More than 50% of patients exposed to anthracyclines show some evidence of 
cardiac dysfunction and of this population, 5% develop congestive heart failure 
(CHF). These effects can develop up to 20 years following the last dose of 
chemotherapy. Anthracycline-induced cardiotoxicity can be a fatal side effect of 
chemotherapy with a mortality rates reported to be as high as 60%, 2 years 
after the last exposure to the drug(1). A retrospective analysis by Swain et al(7) 
who looked at 630 patients diagnosed with congestive heart failure, randomised 
into placebo and doxorubicin group, stated that doxorubicin caused 
cardiotoxicity in 7% of patients manifesting as congestive heart failure, when 
they were given a cumulative dose of doxorubicin >550mg/m2. Their analysis 
which included patients with either breast carcinoma or small cell lung 
carcinoma and indicated that an estimated cumulative 26% of patients would 
experience doxorubicin-related heart failure(7). Retrospective analyses from 
clinical trials suggest that the incidence of heart failure due to doxorubicin is 
seen to be 1.7% at a cumulative dose of 300mg/m2, 4.7% at 400mg/m2 and 
48% at 650mg/m2(8). Although the study acknowledged that epirubicin is less 
cardiotoxic, there was no data to show the cumulative dose of this drug and its 
relationship with incidence of heart failure.  
This clearly shows that anthracyclines cause toxicity of the heart in a dose 
dependant fashion. A study by Bowles et al(9) looked at 12500 breast cancer 




increased, giving a statistical value of 1.2% cumulative incidence after a year 
since the last dose of chemotherapy compared with 4.3% in year 5(9).   
1.5 Detection of cardiotoxicity: 
As anti-neoplastic agents such as anthracyclines cause cardiovascular side 
effects it is important to detect pre-existing heart problems prior to treatment, as 
well as obtaining baseline measurements and monitoring the activity of the 
heart throughout the duration of treatment to observe for any cardiotoxic 
effects(10).  One of the first changes that are often looked for is reduction in 
LVEF and the two gold standard imaging techniques used to detect such 
changes are echocardiography and Multigated Radionuclide Angiography 
(MUGA) scanning(10).  
1.5.1 Conventional Echocardiography 
Echocardiography is a facility that is widely available in most district general 
hospitals where tissue Doppler imaging recordings are used in order to 
measure parameters such as ejection velocity, LV deformation and deformation 
rate which are closely linked to myocardial function(11). Although the use of 
cardiac imaging is first line to detect cardiotoxicity, echocardiography and 
Doppler are limited by technique-related variability which can alter the threshold 
of defining cardiotoxicity. Furthermore, when LVEF is detected, it is often a late 
feature of cardiotoxicity with only 58% recovering systolic function thereafter(12). 
Another drawback of echocardiography is that the observations are inaccurate 
in around 20% of cases such as in patients with high BMI.  
1.5.2 MUGA scans                                 
 Multigated Radionuclide Angiography (MUGA) is a non-invasive technique and 
less widely available facility whereby the radionuclide 99MTc binds to 
erythrocytes facilitated by stannous chloride, which causes the dilution of 99MTc 




camera(13).  At each stage of the cardiac cycle there are a series of heart planar 
images which allow highly reproducible volumes of the left ventricle and 
accurate measurements of LVEF. MUGA scans have high sensitivity and are 
very specific in assessing ejection fraction. Furthermore, no inter and intra-
observer variability are involved which is a beneficial feature compared to 
echocardiography as these variabilities should be considered during LVEF and 
contractile dysfunction measurement by using techniques such as tissue 
velocity and strain imaging. However a limitation of MUGA scans is that its 
function may be disadvantaged by soft tissue attenuation artefacts which may 
expose patients to ionising radiation(14). Another limitation is that different 
MUGA scans are configured differently from each other depending on the 
model and software parameters which might affect the threshold for normality. 
1.5.3 The role of biomarkers 
Although LVEF is used to monitor systolic function during and after 
chemotherapy, it is not efficient in earlier diagnosis of toxicity in the function of 
the left ventricle (15). Several studies have looked at biomarkers in the diagnosis 
of cardiotoxicity. Cardiac biomarkers include cardiac troponin I (cTNI) and T 
(cTNT) which are used to detect myocardial damage. Unlike troponin C, cTNI 
and cTnT are sensitive and specific to the cardiomyocytes and their role has 
been extended to detect other clinical damage such as left ventricular 
hypertrophy and heart failure(16).   
For example, Sawaya et al(15) assessed ultrasensitive troponin I in eighty-one 
newly diagnosed human epidermal growth factor receptor-2 positive (HER2+) 
breast cancer patients treated with anthracyclines followed by the monoclonal 
antibody trastuzumab. It was found that ultrasensitive troponin I predicted the 




were at their peak when the anthracycline treatment was completed(15). This 
shows that ultrasensitive troponin I is useful in predicting cardiotoxicity and may 
guide in detecting cardiac complications after the completion of anthracycline 
therapy. The population that was looked at by Sawaya et al(15) had had a low 
incidence of symptomatic heart failure and cardiac mortality therefore the 
question of why ultrasensitive troponin I is not used routinely remains 
unanswered, as a much greater number of patients with longer follow-up is 
required(15).  
Several studies have also explored the role of natriuretic peptides. These are 
cardiac neurohormones released from the atria known as atrial natriuretic 
peptide (ANP), and brain natriuretic peptide (BNP). They are released 
predominantly from the ventricular myocytes in response to increased wall 
stress. Roziakova et al(17) who looked at patients receiving anthracyclines such 
as daunarubicin, reported that the concentration of BNP and elevated 
concentrations cardiac troponin T correlated with significant changes in systolic 
and diastolic parameters obtained from echocardiographic images, in thirty-two 
out of thirty-seven subjects and only five patients developed manifestation of 
cardiotoxicity. They also reported that this result may indicate a relationship 
between myocyte damage and myocardial impairment(17).  This signifies the 
close correlation between natriuretic peptides and the detection of 
anthracycline-induced myocardial injury. When taking this into consideration, it 
is clear that the limitations of biomarkers are similar to those of cardiac imaging, 
in that they can only detect cardiotoxicity when functional impairments arise. 
Thus novel biomarkers, sensitive enough to detect changes prior to cardiotoxic 




1.6 Prevention of cardiotoxicity 
There are some risk factors that are related to chronic progressive cardiotoxicity 
including cumulative dose, rate of dose delivery, pre-existing heart defects and 
hypertension as well as mediastinal irradiation(18). Several preventative 
measures to reduce the risk of cardiotoxicity have been proposed, including 
limiting cumulative doses of chemotherapy, varying the dose of anthracyclines 
and using less cardiotoxic anthracycline analogues. However, the addition of 
cardioprotective agents and detection of early signs of cardiotoxicity by 
biomarkers are more promising strategies(8). Additionally the use of drugs such 
as desferoxamine which binds iron to aluminium, reduces the iron overload in 
patients on anthracyclines(50). 
1.6.1 Epidemiology of breast cancer 
Breast cancer (BC) is the second most common cancer after lung cancer in the 
western world and it is reported to be increasing in prevalence(19). For example 
in 2006 over 200,000 women were affected by breast cancer in the USA with a 
death rate of 56000 individuals and although the incidence of breast cancer is 
increasing an consistent improvement in 5 years survival rate has been 
observed(20, 21). This is in part due to new screening programs which have 
allowed for increased detection and diagnosis of breast cancer(22). Due to the 
earlier median (40-59 years old compared with other types of cancer where the 
median age is 60-70 years) age of breast cancer diagnosis compared to other 
cancers, there is a slightly higher probability of developing cancer before the 
age of 60(19).  
1.6.1.1 Prevalence of breast cancer 
Breast cancer is the single commonest cause of death among women, 
accounting for about a fifth of death cases in patients between 40-50 years old. 





and 15 will have had their diagnosis made before the age of 50 which equates 
to a prevalence of almost 2%(23). With the advance of treatment and knowledge 
of cancer, treatment has become more customised based on the type of 
tumours including the over expression of HER2 which involves 20-30% of all 
breast cancers. This equates to an absolute value of 40,000 – 60,000 American 
patients suffering from HER2+ type of BC(20).  
1.6.1.2 Incidence of breast cancer 
Based on an article by Ferlay et al(24) the incidence of breast cancer was 
reported to be 1.67 million new cases in 2012 equating to 25% of all cancers 
worldwide. With 198,000 deaths in developed countries and 324,000 in less 
developed regions, incidence rates vary approximately fourfold between 
different regions of the world ranging from 27 per 100,000 in Middle Africa and 
Eastern Asia to 96 per 100,000 in Western Europe. As BC now has a better 
prognosis than ever before, mortality rates between different regions of the 
world are lower, especially in the developed regions where treatments are more 
advanced(24). 
1.6.1.3 Risk factors of breast cancer 
Despite the classic risk factors such as age, family history, age of menarche, 
age of menopause and radiation exposure, there are modifiable behavioural risk 
factors such as physical inactivity, obesity, smoking and excessive alcohol 
intake which creates an overlap with cardiovascular risk factors(23). In addition to 
these risk factors up to 10% of breast cancer cases are due to genetic 
predisposition particularly in the western world(27). The BRCA gene, which is 
expressed in the breast tissue predominantly, expresses tumour suppressing 




45% somatic mutations in tumours result in failure to repair the damaged 
DNA(25).   
1.6.1.4 Detection of breast cancer 
There are several methods of detecting BC. Mammograms are a radiographic 
imaging tool whereby the image density depicts breast epithelium, and it 
associate it with BC. The higher the density of the mammographic images the 
higher the risk of BC. Boyd et al(26) have stated that women with increased 
density covering ≥75% of the breast tissue have a four to six time greater risk of 
BC compared to their counters who have little or no dense tissue. The literature 
indicates that although high density images provide accurate evaluation of the 
breast tissue, they fail to detect breast cancer at its early stages(26). This 
suggests that there is an increased risk of BC development between screening 
tests. 
Another method of diagnosing breast cancer is ultrasound, as mammograms 
can miss breast cancer in more than 50% of patients with dense breast 
tissue(27). The detection of BC has been reported to increase via the use of 
annual ultrasound, allowing for a detection rate of 5.3 cancers per 1000 females 
in the first year. Berg et a(28) stated that using supplemental ultrasound in 
conjunction with MRI or mammography, was less likely to prompt unnecessary 
biopsy or recalling the patients(28). Using this extra method prevents extra 
financial costs and saves time for both the patient and the healthcare provider.  
In certain women who are at high risk of breast cancer, MRI scanning is another 
method that can be used along with annual mammography. MRI has the added 
benefit of detecting features that may have been missed by both mammography 




visualise soft tissue even if a patient has dense breasts or implants as the 
scanner utilises magnetic field to create a visual presentation(29).  
 
Unfortunately MRI fails to detect all types of breast cancer although it is the 
method of choice for detecting certain subtypes such as ductal carcinoma in-
situ and lobular breast cancer are difficult to detect(29). These disadvantages, 
combined with the cost of MRI means that it is not the most cost-effective way 
of detecting breast cancer. Additionally, a biopsy of the breast can be examined 
in order to determine the existence of breast carcinoma microscopically. 
Although the invasive nature of this investigation is a down side, biopsy is the 
gold standard method for detecting cancer(29).  
1.6.1.5 Treatments of breast cancer 
Although there are several ways of treating breast cancer, there are three main 
categories; surgical treatment and systemic treatment and radiotherapy; each 
section explores the available treatment options and their relevant side effects. 
Additionally BC treatments that are associated with cardiotoxicity are also 
described. 
1.6.1.5.1 Surgical intervention 
Mastectomy is the oldest method used in the treatment of breast cancer where 
one or both breasts are removed either partially or completely. Surgical removal 
of the breast can also be used as a prophylactic measure in patients who are at 
higher risk e.g. family history of BC or a previous incidence of BC with a number 
of lesions and or in patients suffering from multifocal disease.(30).Though the 
invasive nature of this procedure is a disadvantage, in that with many other 
operations it involves side effects such as post-surgical infections, buildup of 




prophylactic mastectomy reduces the risk of BC occurrence and offers 
psychological assurance to the patients. 
Lumpectomy, also known as wide local excision is used to remove a portion of 
the breast or a lump containing the tumour in women with intraductal breast 
cancer (ductal carcinoma in situ) and lobular carcinoma(31). The aim of 
lumpectomy is to conserve the unaffected breast tissue which offers both 
physical (i.e. quicker recovery) and psychological satisfaction as the breast 
tissue does not drastically change cosmetically. 
Ensuring an oncologically safe resection of breast tumours often generates 
unsatisfying cosmetic results and for many years oncoplastic surgery (OPS) has 
been used in order to overcome this challenge. This approach combines the 
principles of surgical oncology with plastic surgery in order to ensure optimised 
oncologic safety while maintaining a good cosmetic outcome. OPS offers 
advantages such as wider excision of the tumour while maintaining the overall 
shape of the breast, although it can be more complicated than mastectomy, 
reduced waiting time and the elimination for a complex reconstructive 
surgery(32).  
Adjuvant radiotherapy is also used following chemotherapy or surgery, to 
decrease the risk of local recurrence whereby Ionising radiation is used to kill 
malignant cells in a localised area of the body. Unfortunately radiotherapy is 
also toxic to the heart and there is a higher risk of heart failure and 
cardiovascular mortality especially in patients with left-sided breast tumours as 






1.6.1.5.2 Systemic intervention 
As well as surgery there are a variety of systemic treatment options used in the 
management of breast cancer, including chemotherapy, hormonal therapy and 
molecular targeted therapy. Many of the chemotherapeutic agents available 
today work by potentiating cytotoxic effects that damage the DNA in order to 
stop the abnormal cell division. One down side of these agents is that they can 
be non-selective, meaning that they also target cells with normal DNA and 
normal division(34).  Some of the most commonly used classes of drugs include 
alkylating agents, Anthracyclines, anti-metabolites and Taxanes(34). As this 
project’s main interest is Anthracycline-induced cardiotoxicity, Anthracyclines 
and their combination with other drugs used in the treatment of breast cancer 
are discussed only.  
Hormonal therapy 
The use of hormonal therapy as an adjuvant, increases BC survival significantly 
in oestrogen receptor-positive patients. It is critical to continuously use adjuvant 
hormonal therapy after a patient finishes their chemotherapy in order to improve 
survival. Tamoxifen, a selective oestrogen receptor modulator (SERM) is often 
prescribed for up to 10 years as a preventative measure in hormone-receptor 
positive women(35). Prolonged stimulation of the ductal epithelium in the breast 
by oestrogen contributes to the development of BC and tamoxifen inhibits the 
oestrogen receptor (ER) to reduce this effect(36). 
Aromatase inhibitors are another class of drugs used in the treatment of breast 
cancer which provide novel approaches to the endocrine treatment of breast 
cancer. Aromatase is an enzyme of the cytochrome P-450 superfamily, is highly 





extent in normal and adipose tissue(37). They work by supressing plasma 
oestrogen levels in post-menopausal women by inhibiting or inactivating 
aromatase, which is the enzyme responsible for the synthesis of oestrogen from 
androgenic substrates(37). Although aromatase inhibitors can be seen as 
challenging tamoxifen, they are the only gold standard group of drugs for post-
menopausal treatment.  
1.7 Breast cancer treatment and cardiotoxicity 
1.7.1 Anthracyclines  
Anthracyclines are highly potent cytostatic antibiotics that have been used 
clinically for almost half a century. They exert their effect via the inhibition of 
topoisomerase II (TOP2), an enzyme involved in cutting the strands of the DNA 
helix to induce cell death(8). As effective as they are in treating certain types of 
solid tumours, they are highly toxic to the heart and intercelate the DNA within 
the cells. Many theories have been proposed to explain their cardiotoxic 
mechanism but none have been proven(38). The most accepted theory is that 
anthracyclines cause oxidative stress via the formation of reactive oxygen 
species, through different pathways. One of the most commonly known 
pathways is that anthracyclines enter the cell causing redox cycling leading to 
the generation of oxygen free radicals in the mitochondrial respiratory chains(8).  
Other mechanisms that have been speculated are the accumulation of toxic 
metabolites and alteration in iron metabolism where Fe-anthracycline 
complexes are generated and further increase oxidative stress. As this is only at 
theory level, many have suggested that toxicity due to the combination of iron 






This is due to the fact anthracyclines can alter iron homeostasis through the 
production of oxygen free radicals(38).   
1.7.2 Targeted therapies:  
Patients who are HER2+ may also be given the drug Herceptin (Trastuzumab) 
as an adjuvant treatment as trials have shown statistically significant reduction 
in recurrence risks by almost 50% and by one third in overall survival(20). 
However, the risk of iatrogenic cardiotoxicity increases when anthracyclines are 
combined with molecular targeted therapies such as Herceptin. HER2 positive 
patients are more likely to have lymph node involvement, higher aggression of 
tumour progress, decreased expression of oestrogen receptor and increased 
resistance to endocrine therapy(27). This review will only focus on anthracyclines 
and herceptin, as there is a higher association of cardiotoxicity with these two 
drugs than any other anti-neoplastics. Furthermore this study will focus on the 
patients with breast cancer who have been treated with these two agents. 
Studying this group offers advantageous data as the survival rate in breast 
cancer is high and patients often complete the treatment regimen successfully 
which allows accurate calculation of the cumulative dose of therapy from start to 
finish. Herceptin, a recombinant humanised monoclonal antibody targets HER2 
as it is up-regulated in some breast cancer patients. Its mechanisms of action 
include the reduction of signal transducers such as PI3 kinase and MAP kinase 
cascades which are activated by HER2. The reduction in receptor signalling 
promotes apoptosis and cycle arrest which may result from internalisation and 
degradation of the HER2 receptor(39). Unfortunately though, Herceptin is been 
associated with cardiac dysfunction and cardiotoxicity with an incidence of 





Although the exact pathophysiology of Herceptin-associated cardiotoxicity 
remains largely unknown, it is thought to be due blockage of HER2 receptor, 
which under normal circumstances protects the cardiomyocytes from stress 
when exposed to anthracyclines(40). 
Cardiomyocytes are constitutively active cells and they have a high energy 
demand for ATP. When Herceptin binds to HER2, its high affinity binding 
dampens PI3K and MAPK signalling, meaning the mitochondria become more 
prone to the generation of Reactive Oxygen Species (ROS), as it cannot 
maintain the need for ATP production. Unlike anthracyclines, Herceptin-induced 
toxicity is reversed when it is discontinued and there is no evidence of dose-
dependent cardiomyopathy(41). 
1.8 Prophylactic properties of cardioprotective agents: 
Studies at animal and human level, have shown evidence of cardioprotection 
when prophylactic cardioprotective agents are initiated early enough at the 
beginning of the course of chemotherapy. In this section the agents will be 
explored individually to shed light on their protective mechanisms and the 
pharmacological approaches that may be used to potentially reverse 
cardiotoxicity. 
1.8.1 Cardioprotective Human studies and clinical trials 
1.8.1.1 ACE inhibitors  
ACE inhibitors have been shown to have beneficial effects on anthracycline-
induced cardiotoxicity. However the full spectrum of how this occurs remains 
poorly understood(42). Some believe that the inhibition of ACE could cause a 
reduction in interstitial myocardial fibrosis or even attenuate oxidative stress, 
leading to improved calcium handling which improves overall myocardial 





A study conducted by Cardinale et al(43) involved ACE inhibitors and looked at 
473 high-dose chemotherapy (HDC) patients who received different cumulative 
doses depending on whether they had previously undergone anthracycline 
therapy or not, with an elevated troponin I. These were divided into placebo and 
enalapril groups and treatment was started one month after HDC was given. 
The study reported a lower incidence of adverse outcomes such as in LVEF 
impairment and increases in end-diastolic pressure (EDP) and end-systolic 
pressure (ESP), in the ACEi group compared to the control. It was concluded 
therefore that the group treated with ACEi had significantly lower levels of 
developing cardiotoxicity (P<0.001)(43). One limiting factor of a human based 
study with a high number of participants is that many of the cancer patients 
have different chemotherapeutic regimens thus their response to different 
cardioprotective agents may be altered.  
1.8.1.2  β-blockers  
There is growing evidence that inhibitors of β-adrenergic signalling mitigate 
cardiotoxicity associated with anthracyclines, though the exact mechanism 
remains unexplained(8). Studies have shown that carvedilol prevents 
anthracycline-induced cardiomyopathy and the development of free radicals(44). 
For example Kalay et al(44) studied a group of patients with a malignancy that 
required anthracyclines and randomised them into carvedilol prior to 
chemotherapy for 6 months as the patients were receiving chemotherapy, or 
placebo and evaluated their cardiac function via echocardiography. The control 
group had a significant reduction in their ejection fraction (EF) of 68.9 vs 52.3 
(P<0.001), whereas the group that received carvedilol had an ejection fraction 




included a follow up period of six months during which time it is unlikely for 
many patients develop a worsening heart function(44).  
Another limiting factor is the number of subjects they used in this study as they 
only looked at 25 participants in each group. A larger population over a longer 
period of time would produce a more realistic perspective. 
In a randomised controlled study by Kaya et al(45) which looked at the 
cardioprotective effects of nebivolol, an increase in LV end-diastolic and end 
systolic diameter was observed in the placebo group compared with unchanged 
diameter in the nebivolol group. The placebo group also had developed a lower 
LVEF of 57.5% compared to 63.8%. In the nebivolol group this was statistically 
significant, as a P value 0.001 was achieved. Although the methodology was 
similar to the carvedilol study, this trial administrated nebivolol prophylacticly 
prior to the initiation of anthracyclines(45). The size of the study group was also 
small as there were only 27 participants who were assigned to nebivelol and 18 
for placebo. This again raises questions regarding the power of the 
results/study. 
1.8.1.3 Statins  
For years it has been speculated that statins could be used as a 
cardioprotective agents in cancer patients to reduce anthracycline-induced 
cardiomyopathy(8). A retrospective study looked at 628 female breast cancer 
patients with a mean age of 51 years who were receiving anthracyclines. The 
primary outcome of incident HF and hospitalisation was compared between 
those receiving statin therapy with those who did not. The findings showed that 
those who received statins had a significantly reduced hazard ratio of 0.3 and a 






Although these results are promising, medication records and stage/dosage of 
chemotherapy data were not fully obtained, meaning other potentially 
cardioprotective agents such as ACEi and β-blockers could have influenced the 
results.   
1.8.1.4 Metformin  
Interestingly the biguanide Metformin has shown to have many cardioprotective 
properties and it is thought to reduce the generation of ROS via the activation of 
5’-adenosine monophosphate-activated protein kinase (AMPK) as it has been 
observed in animal models of HF(47). Despite these promising findings, such 
studies are primarily on animal models and few preliminary studies have been 
done at human trial level. Although metformin treatment can reduce cancer-
related mortality in diabetic patients, it is unclear whether the use of metformin 
translates into improved clinical outcomes for patients who are receiving 
standard cancer therapy. Thus the use of metformin does not necessarily 
suggest effective therapeutic efficacy in diabetic patients with an established 
cancer(48). 
Bosco et al(49) emphasised the power of metformin’s cardioprotective properties 
by looking at 24 women who were on metformin and had BC. It was found that 
patients on metformin had 40% reduced risk of BC compared with non-
metformin users(49). An indication of the total number of population looked at by 
Libby et al would have given a better scope of the overall rate of BC 
development in metformin patients. It can be seen that the question of how 






1.8.1.5 Dexrazoxane   
Dexarazoxane is an iron chelating agent that changes the TOP2 
configuration by tight binding to its ATP-binding sites and preventing 
anthracyclines from binding. It is an effective drug with cardioprotective 
properties and it is the only FDA approved drug used against anthracyclines 
induced cardiotoxicity. Its mechanism of action involves chelating iron thus 
reducing the number of metal ions that are produced by anthracyclines. It is 
thought that this leads to a reduction in free radicals which ultimately 
decreases oxidative stress(50).  
Lipshultz et al(51) assigned two groups of children with acute lymphoblastic 
leukemia into either receiving doxorubicin alone or daxarazoxane followed 
by doxorubicin, in an attempt to demonstrate whether the free radical 
scavenging drug decreases cardiotoxicity associated with anthracyclines. 
They observed an increase in troponin T, a measure of cardiac damage in 
35% of the participants who were treated with doxorubicin alone(51). 
Although there were no significant echogardiographic changes between the 
two groups, it was concluded that dexarazoxane prevented or at least 
reduced doxorubicin-induced cardiotoxicity as reflected by troponin T 
elevation. They also observed an 83% event-free survival at 2.5 years since 
the last dose was given in both groups(51).  
1.9 Cardioprotective animal studies 
1.9.1 ACE inhibitors  
In an animal study El-Aziz et al(52) evaluated ACE inhibitors Enalapril and 
Captopril for their anti-oxidative protective actions against anthracycline-iduced 
cardiac and hepatic toxicity, in rats who were randomly treated with one of the 





Upon an increased lactic dehydrogenase (LDH) and lipid peroxidation which are 
thought to be markers of anthracycline-induced cardiotoxicity, both ACE 
inhibitors improved the serum levels of LDH as well as other hepatic enzymes 
such as glutamic oxaloacetic transaminase, indicating that they possess 
antioxidative properties that could have the potential to protect the heart(52).  
These findings are consistent with other groups who demonstrated the 
scavenging action of captopril both in vitro and in vivo in order to reduce 
superoxide radicals, thus reducing the onset of myocardial dysfunction. 
Furthermore ACE inhibitors were found to significantly enhance glutathione-
dependant anti-oxidant defences(52). 
1.9.2 β-blockers  
In a study by de Nigris et al(53), the cardioselective beta-blocker nebivolol and 
the non-selective beta-blocker carvedilol were used in Sprague Dawley rats 
between 10-12 weeks old, who were treated with either doxorubicin or 
daunorubicin. Their hearts were isolated and perfused via a cannula in the 
aortic root and remained at a constant pressure of 90mmHg. At different time-
selected points the levels of oxidative stress, cardiac damage and nitrate were 
evaluated and the results revealed that oxidative stress pathways were 
improved significantly by the addition of beta-blocker. With regards to the action 
of the individual beta-blockers, nebivolol presented more prominent 
cardioprotection compared to carvedilol(53). This could be due to the fact that 
nebivolol has additional vasodilating properties that are not shared with any 






1.9.3 Statins  
The anti-hypercholesterolemic drug Lovastatin is an inhibitor of 3-hydroxy-
3methyl-CoA reductase, an enzyme involved in the metabolic pathway that 
produces cholesterol. In vitro studies have shown that lovastatin reduced 
doxorubicin-induced cardiomyocyte death and reduced DNA damage by 
mediating TOP2, which is thought to be due to impaired RAC1 signalling. RAC1 
inhibition has been shown to attenuate doxorubicin-induced cardiotoxicity. 
Lovastatin was also found to blunt the elevation of troponin I after exposure to 
doxorubicin(8). Studies have also shown that the statin known as fluvastatin, 
through its antioxidant and anti-inflammatory properties, reduced LV dysfunction 
in mice exposed to doxorubicin(8). 
Another study by Feleszko et al(54) examined the cardioprotective effects of 
statins in the context of anthracycline use. 11-15 week old female mice were 
divided into three different tumour models of 3T3 sarcoma cells, Lewis lung 
carcinoma cells and colon cells. They found that the addition of lovastatin 
resulted in a significant reduction of troponin T levels in mice who were given 
doxorubicin. These findings are in agreement with previous studies that have 
shown that lovastatin reduces doxorubicin-induced cardiac injury. Another 
interesting finding was the fact that there was a significantly higher sensitivity to 
the combined treatment with both lovastatin and doxorubicin as compared with 
either agent acting alone leading to a more effective decrease in the viability of 
cardiomyocyte damage than each agent alone(54). The introduction of lovastatin 
could therefore be looked at as a possible treatment approach in patients who 






damage. Although these findings are promising, there is currently insufficient 
data to support their use in humans.  
1.9.4 Metformin  
A study by Ashour et al(55) used adult male rats and divided them into separated 
groups where some were injected with saline only, some with doxorubicin only 
and some with metformin + doxorubicin. As predicted, electron microscopy and 
histopathology evaluation showed that metformin significantly protected against 
doxorubicin induced cardiac injury by preventing doxorubicin from reducing 
cardiac levels of CoA-SH (also known as Coenzyme A) which is involved in the 
synthesis and oxidation of fatty acids and transferring them to the mitochondria. 
A key finding of this investigation is that cardiotoxicity in the metformin group 
was found to decrease as acetyl-CoA levels increased(55). This rise in acetyl-
CoA gives the impression that mitochondria in the cardiomyocytes, which are 
important sources of energy and ATP production, may be restored leading to a 
further reduction of free radicals(55). 
1.10 Review Summary 
Despite current advancements in cancer therapy, the biochemical and 
molecular changes involved in anthracycline-induced cardiac damage 
remain poorly understood. In the context of detecting cardiotoxicity, cardiac 
imaging techniques are limited in that detection of cardiotoxicity is usually 
late and irreversible at this stage. Therefore, more novel imaging techniques 
are clearly required. 
In order to prevent cardiac damage, the cumulative dose of anthracyclines 
has to be limited which results in a reduced efficacy that may not produce 





find novel approaches to reduce or even completely prevent chemotherapy-
associated cardiotoxicity, to allow for optimal anti-cancer therapy to be 
given. 
Although animal studies have suggested that commonly used 
cardioprotective drugs such as the ones named above could potentially 
have a role in reducing cardiotoxicity, the translation of these findings to 
humans remain unknown. The aim of this study is to explore the potential 
benefits of cardioprotective drugs including ACE inhibitors, beta-blockers, 
statins and metformin in patients receiving chemotherapy for breast cancer, 
to see if they could be initiated prior to chemotherapy to prevent or reduce 
chemotherapy-induced cardiotoxicity. This will be assessed using outcome 
endpoints such as new-onset of heart failure, worsening heart function on 
echocardiogram, cardiovascular mortality and hospitalisation due to heart 
failure, myocardial infarction and stroke. The findings of this study may have 
the potential to discovering novel therapeutic strategies for this adverse 






2 Chapter 2: Methodology 
2.1 Study design: The study was an observational population-based 
cohort study that was undertaken using data linkage of cancer registry, 
dispensed prescriptions and death records in Tayside, Scotland. Following 
Research and Development (R&D) and Caldicott Guardian Approvals, data for 
a total of 1282 breast cancer patients of which 1229 were eligible for analysis 
(see figure 1), was collected from the oncology ward at Ninewells Hospital in 
Tayside. CHEMOCARE (n=12,133 records), an electronic chemotherapy 
prescribing and patient scheduling system database was used to search for 
breast cancer patients who underwent chemotherapy. Once suitable patients 
were identified, parameters such as the start and end date and cumulative dose 
of anthracycline(s), as well as the start and end date and cumulative dose of 
herceptin (Trastuzumab) were manually extracted using the Wisdom database. 
This is a database used by the oncology and haematology departments and 
holds records of visit outcomes, a brief medical history of the patient, general 
status of the patient’s wellbeing, dates of each cycle and date of death for 
deceased patients. 
 Upon the completion of data collection, all community prescriptions for ACE 
inhibitors, β-blockers, statins and metformin, for each individual were extracted. 
Demographic data (age, gender, etc.), cardiovascular comorbidities, 
biochemistry & haematology blood results, imaging (echocardiography and 
MUGA scans), as well as Scottish Morbidity Record (SMR01), and General 
Registry Office (GRO) death records were extracted via the Health Informatics 
Centre (HIC). The Health Informatics Centre is a University of Dundee research 





medical Science Centre (TASC) that holds records of all dispensed 
prescriptions since 1993 for all individuals (n=approximately 400,000) in 
Tayside which have been collected and stored by Medicines Monitoring Unit 
(MEMO) and subsequently at HIC.  
It administers access to validated data sets that have been anonymised using 
protocols approved by the Research Ethics Committee in Tayside on a virtual 
environment known as Safe Haven.   
2.2 Study Population: All patients (≥18 years of age) who were newly 
diagnosed with biopsy-confirmed breast cancer who underwent anthracycline-
based chemotherapy or a combination of herceptin with an anthracycline in the 
case of HER2+ patients, at NHS Tayside between January 2003 to December 
2014 were identified using chemocare. The date of the first cycle of 
chemotherapy and in some cases the date of the cancer diagnosis confirmation 
was considered the entry date of the study. Hypertension, diabetes, smoking 
any cardiovascular complications, coronary artery disease (CAD), chronic 
obstructive pulmonary disease (COPD), cardiac dysrhythmias, depression, 
overweight or obesity were the recorded co-morbidities. Patients on 
cardioprotective drugs (ACEi & β-blockers), cholesterol lowering agents 
(Statins) and the anti-diabetic drug Metformin were also identified using the 
wisdom database at or before the start date of chemotherapeutic regimen.  
A variety of risk factors for cardiotoxicity was resulting from baseline 
characteristics which was considered to be positive for individuals less than 55 
years old who had a history of hypertension, history of smoking, coronary artery 





2.3 Outcomes: The primary endpoints of interest were: 
 1) worsening left ventricular function on echocardiogram and/or  
 2) worsening left ventricular function that required the loop diuretic furosemide,  
3) cardiovascular mortality and  
4) new onset of heart failure that required hospitalisation after the initiation of 
anthracycline treatment, including hospital admission due to myocardial 
infarction and stroke. This was done using International Classification of 
Disease-Tenth Revision (ICD-10) diagnosis codes I09.9, I11.0, I13.0, I13.2, 
I25.5, I42.0, I42.5 – I42.9, I43., I50., P29.0.  
2.4 Statistical Analysis:    
 
 Drug exposure to different classes of drugs (ACE, ARB, BB, CCBs, Anti-
platelets, Metformin, Sulfonylureas, Insulin & TZDs Statins during the follow-up 
was determined from the prescribing records. 
Each patient’s follow-up continued until either date of death or the end of follow-
up date (earliest of each latest date of availability for SMR01, NRS, Prescribing, 
Echo & MUGA datasets) 
The Cox proportional hazard model 
The Cox proportional hazard model included age, sex, gender, baseline heart 
function, eGFR and baseline use of ACE inhibitors, beta-blockers, statins and 
metformin as independent variables and the data will be right censored if there 
is an outcome-endpoint (heart failure, worsening heart function on 
echocardiogram or MUGA scans, cardiovascular mortality and cardiovascular 




Separate analysis was conducted for each of the outcome measures.  
If the baseline use of drugs shows protective effect on outcome-endpoint the 






Breast Cancer and Cardiotoxicity; A 10-Year Audit 
 
Different national and international guidelines are available to monitor cardiac 
function in patients undergoing chemotherapy. They recommend patients 
planned for potentially cardiotoxic chemotherapy regimens to undergo 
cardiovascular assessments prior, during and after treatment, to identify 
cardiovascular complications. However despite the availability of these 
guidelines, it is unknown whether they are being adhered to in clinical practice. 
Additionally, the incidence of chemotherapy induced cardiotoxicity in the local 
hospital and how rigorously are patients surveyed as per these guidelines. 
Therefore, an audit was performed as a sub study of the main project with the 
aim of examining the assessment and incidence of cardiotoxicity in breast 
cancer chemotherapy over a 10-year period.  
Methods:                                                                                                                                                       
Following Caldicott guardian approval, a retrospective population cohort study 
was conducted at Ninewells Hospital and Medical School, a large teaching 
hospital in Tayside, Scotland. 1283 patient notes were initially screened using 
Tayside CHEMOCARE database of which 54 patients had no records of 
chemotherapy regimens (e.g. cumulative dose, start and end date of therapy 
etc) leaving 1229 eligible patients to be studied for the audit (See figure1). 
Records such as type of anthracycline, adjuvant radiotherapy, combination  
therapy (anthracycline + Herceptin), and age were captured from January 2003 
to December 2014 to determine compliance with guideline-mandated 
monitoring of LV function and incidence of LVSD and HF during and up to 1 
year post chemotherapy. A record data linkage was established through Health 




large amounts of anonymised data sets are stored. Data from echocardiography 
database (>100,000 echo data) was linked which uses a validated natural 
language algorithm to identify LV dynsfunction (Elder DH et al. JACC 2011; 58: 
2084-91; Swejkowski BR et al. Eur J Heart Fail 2012; 14: 162-7)(56, 57).    Other 
imaging modalities such as MUGA scans were extracted using the GE Xeleris 
software used by the nuclear medicine department to look at LVEF and 
determine which patients are at risk of LV dysfunction. These MUGA scans 
were filtered accordingly as many patients had multiple scans. This gave the 
opportunity to look at the dates between different scans which gave a general 
prospective of which patients were receiving subsequent scans during the 
course of treatment. Other records such as prescribing data for Furosemide and 
cardiovascular drugs and Scottish Morbidity records (SMR01) for heart failure 








Figure 1 -  Concort Figure of Population used for audit  
 







Breast Cancer (1283) 









All baseline screenings for cardiac assessment were performed prior to or 
within 6 weeks of commencement of chemotherapy. This may seem to be a 
rather long period for baseline screening, however long waiting times are the 
main cause for such delays. These delays are sometimes inevitable as a patient 
may need a MUGA scan prior to the commencement of chemotherapy as safety 
is paramount. Of the 1229 patients only 625 (50.9%) underwent baseline 
cardiac assessment (mean ejection fraction 63.2% ± 7.0%) of which 238 
(38.1%) had subsequent follow-up scans. All assessments were using MUGA 
scans and all patients had normal left ventricular ejection fraction (≥55%) with 
low baseline cardiovascular risk (hypertension 16.1%; diabetes 7.0%; ischaemic 
heart disease 3.3%) who were treated with guideline-based adjuvant 
chemotherapy regimens (mean cumulative doses: epirubicin 599 ±281mg/m2; 
doxorubicin 559 ±143mg/m2).  
However, when patients were divided based on treatment regimes, we found 
85.7% of patients treated using anthracyclines plus trastuzumab had LV 
function assessment at baseline and 96.9% of them had follow-up scans. This 
contrasted with the anthracycline only group where only 43.1% had baseline 
scans and a mere 12.2% were followed-up. This may be due to the belief of 
some healthcare providers that those who are on combination therapy may 
develop left ventricular systolic dysfunction quicker than those on anthracycline 
therapy alone.  
National and International guidelines mandate the monitoring of the left ventricle 




such as echocardiography and/or MUGA scans to facilitate early detection of 
LVSD, as signs of cardiotoxicity begin early, during or after chemotherapy(58). 
Incident LV dysfunction 
Incident LV dysfunction was defined as per guidelines as follows: 
• reduction of LV function by >10% AND ejection fraction of <50% 
• reduction of LV function by 10% 
• Worsening in qualitative LV function on echocardiogram 
• Ejection fraction of <45% at anytime after baseline 
• Increase in mild LV systolic dysfunction (qualitative assessment) 
• Hospitalisation for heart failure AND prescription of the loop 
diuretic Furosemide.  
The incidence of left ventricular systolic dysfunction up to a year after the 
completion of chemotherapy was 8.1% overall, 11.7% in the anthracycline plus 
trastuzumab group and 7.4% in the anthracycline only group. This is in 
agreement with the literature as the incident of LV dysfunction and cardiotoxicity 
increases significantly when patients receive a combination of anthracycline and 
Herceptin. The results of incidence of LV dysfunction along with other 






3 Chapter 3: Results 
 
As mentioned in section 6.4 of methodology section, Cox proportional hazard 
model which included different parameters as independent variables was used 
to right censor the data if an outcome-endpoint such as heart failure and 
worsening heart function was confirmed. However, the analysis found a weak 
statistical signal associated with the use of cardioprotective drugs and the 
prevention of chemotherapy-related cardiac damage (p = NS). This in part was 
due to a low number of patients for the study. As the audit was done on the 
same study population and used the same imaging modalities, shared results 
were achieved and are demonstrated together below. 
The demographics of patients who were studied in the audit have been 
tabulated below, depicting the majority of the study population to be females as 
breast cancer affects this gender mostly as well as different treatment regimes 
given and their co-morbidities. Of the 1229 patients the majority of the them 
received anthracycline therapy only and only 18.1% of the patients received 
herceptin therapy in addition to anthracycline therapy. This is in agreement with 










 Table 1- Demographics of subject patients studied for a ten-year audit.  
 
Using the statistical analysis from data collected, the cumulative dose of 
anthracycline in patients who received anthracycline alone showed to be 
619mg/m2 with a standard deviation of 269 and in those who received both 
anthracycline and herceptin received a cumulative dose of 499mg/m2 with a 
standard deviation of 235. 
 
Demographics 
Total number of patients (n) 1229 
Female (%) 1225 (99.7 %) 
Mean age 53.84 years ± 10.7 years 
Treatments received 
Patients received anthracyclines 
only (%) 1006 (81.9%) 
Patients on combination therapy 
with herceptin (%) 223 (18.1%) 
Herceptin therapy alone 0 
Co-morbidities  
Type II Diabetes 86 (7%) 




Left ventricle assessment within 6 weeks of starting chemotherapy as well as 
the follow ups after that period of time are illustrated in the table 2. Results from 
this table show a statistically significant p value (<0.001) which show a clear 
evidence that the majority of patients are assessed for cardiac function within 6 
weeks of treatment commencement. However this figure drops (p=0.008) which 
shows many of those patients on anthracycline only regimens do not receive a 
subsequent follow up assessment. 









 Table 2 – Percentage of patients received left ventricular assessment at baseline    in 
both anthracycline (A) only and combination therapy (HA) patients. 
 















630 (282) 606 (251) -  - p=0.03 
- - 552 (117) 490 (243) p=0.009 
Table 3- Cumulative dose of anthracyline received expressed in milligrams/meter 
squared of surface area with the standard deviation (SD), depicting in both assessed 
and not assessed patients. 
 
 A (n= 1006) HA (n= 223) P value 
Assessment 
of LV function        
(within 6w) 
625 (62.1%) - 
434 
(43.1%) 




238 (38.1%) - 
53 
(12.2%) 





Following the numerical explanation of the audit in chapter 3 the incidence of LV 
dysfunction is represented in the table 4 below. Incidence of LV dysfunction in 
table 4, is shown to be lower in patients on anthracycline therapy alone 
compared to those on anthracycline plus adjuvant herceptin therapy.  
 No Heart Failure Heart Failure P value 
Incidence (overall 
population) 
1114 (90.6%) 100 (8.1%) -  
anthracyclines 917 (91.2%) 74 (7.4%) 
}p=0.046 Anthracycline + 
Herceptin 
197 (88.3%) 26 (11.7%) 
Table 4 – Table showing the number of  individual patients with incidence of LV 
dysfunction in both heart failure and no heart failure patients. Incidence is shown in 
different treatment groups (anthracyclines alone or anthracyline + Herceptin). 
 
Different cardioprotective drugs show no significant protection is is provided by 
the drugs, meaning that there is no difference in clinical effectiveness as to 
whether a patient is using these drugs or not except in angiotensin receptor 
blockers (ARBs). An odds ratio of 2.6 portrays that patients on this ARB 
medication are 2.6 times more likely to develop chemotherapy-related heart 
failure. This is unlike what was speculated initially, as it was thought ARBs 
would have cardioprotective properties. This is likely to be an indication of 
insufficient number of study subjects with out-dated medical records. This may 







 No Heart Failure Heart Failure P value 
Anti-platelets 40 (3.6%) 2 (2%) Insignificant 
Statins 99 (8.9%) 6 (6%) Insignificant 
Beta-blockers 75 (6.7%) 6( 6%) Insignificant 
ACE-inhibitors 69 (6.2%) 7 (7%) Insignificant 
ARBs 36 (3.2%) 8 (8%) 0.023 
(OR = 2.6) 
Table 5 – Number of individual patients on different cardioprotective drugs.  
 
Although metformin was also one of the drugs of interest to look at, no data was 
received from health informatics centre at the time of analysis. This could be 
due an error that occurred during data linkage as many patient’s records were 
not up to date. Although the effects of various cardio-protective drugs are 
insignificant, ARB effects have shown to have spurious effects.  Additionally, no 
data on radiotherapy was collected as the main interest was to investigate the 







Different imaging modalities were extracted and looked at separately (see 
chapter (2). The two charts below show the extensive use of MUGA scans 
compared to echocardiography; this in part is due to the fact that MUGA scan 
shows a numerical measurement of ejection fraction which is a robust indicator 
of cardiac function in patients undergoing chemotherapy. 
 
         
                         
 
Figure 2- Modality of LV assessment at 
baseline level                                                                                                                         
(within 6 weeks of treatment 
commencement). 
 
Figure 4 – Modality of LV assessment in 






4 Chapter 4: Discussion 
 
4.1 PROTECT-TAYSIDE study 
As seen in the results section, an underpowered signal has shown that the use 
of cardioprotective drugs such as ACE inhibitors, ARBs, β-Blockers and statins 
do not protect from any chemotherapy-induced cardiotoxicity. In fact it can be 
seen from table 5 that contrary to what was thought, the use of ARBs causes 
further cardiac damage in patients receiving anthracyclines with or without 
adjuvant trastuzumab. Given an odds ratio of 2.6, these patients are more than 
twice as likely to suffer heart failure as a result of using angiotensin blockers. 
One possible reason could be that these patients differ from their counter parts 
who are receiving cancer therapy but not ARBs, in that those on ARBs may 
have have different fluctuations in their blood pressure due to their different 
action of angiotensin blockage. Interestingly this has not been reported 
anywhere else in the literature. The time at which this damage may occur 
(during or after the completion of chemotherapy) was not evaluated. Given the 
fact that this study was a retrospective population cohort study from a small 
region of Scotland, the number of available cases for the study was limited as 
the events have already occurred which is a limitation of retrospective studies. 
Having a larger number of patients for the study from a longer period of time 
would have been advantageous however, there were no digital records of 
patients prior to 2004.  
Different small scale clinical trials have looked at the effects of cardioprotective 
drugs in the prevention of cardiac damage in patients undergoing chemotherapy 
regimes similar to those of this study. An example of such trial is the PRADA 




with early breast cancer in a 2 x 2 factorial randomised, placebo controlled 
trial(59). Patients were divided into four groups and were either given 
candesartan cilexetil and metoprolol succinate, candesartan cilexetil and 
placebo, metoprolol succinate and placebo or placebo and placebo.  
 
Different imaging modalities such as MRI and electrocardiograms were used 
unlike this study where MUGA and echocardiograms were used instead. 
However their examinations were performed at baseline and after the 
completion of the last cycle of anthracycline and in those on adjuvant therapy 
(trastuzumab or radiotherapy) at the completion of the course(59).  The aim of 
the PRADA trial was the same as this study with similar primary out comes such 
as changes in LVEF from baseline to completion of anticancer therapy 
determined by medical imaging. Gulati et al(59) reported no interaction between 
the use of candesartan and metoprolol and no importance was found 
statistically (p=0.53) or on any of their endpoints, which indicates that the drugs 
used did not prevent worsening of cardiac function. Interestingly effects of 
candesartan on changes in LVEF were not affected by adjustment for change in 
systolic blood pressure(59). Although in the PROTECT-TAYSIDE study the 
effects of ARBs were found to be negative (OR 2.6), the overall results are in 
agreement with the PRADA trial.  
Candesartan was found to be ineffective in causing a reduction in cardiac 
troponin I associated with anthracycline containing adjuvant therapy. This 
suggests that the blockade of angiotensin receptors may have no interface on 
cardiotoxic effects of anthracycline directly, but as candesartan showed a 
significantly less reduction in LVEF of patients who were assigned candesartan-




in the processes of remodelling of the myocardial tissue that usually occur after 
cardiac injury(59). This is believed to fit with the literature both in animal and 
human studies.  
With regards to the groups that were assigned to metoprolol, only 0.2 
percentage point difference was seen between those who were on the active 
beta blocker and those on placebo from baseline to end of study. This equated 
to statistically insignificant difference with regards to reduction of anthracycline-
related cardiac damage. Moreover, metoprolol showed no short term beneficial 
effects in the attenuation of the reduction in LV function.  
The results of PROTECT-TAYSIDE study are broadly in agreement with the trial 
described above although the PRADA study only lasted for two years, 
compared with the ten-year prospective cohort analysis.  
Gulati et al(59) believe that although inadequate statistical power was achieved, 
the beneficial effects of beta blockade cannot be ruled out. This projection is in 
agreement with this project. As the PRADA study is a randomized placebo-
controlled trial, the dosage of different drugs used was adjusted by the 
investigators. As an example a moderately high dose of metoprolol was attained 
which showed a reduction in heart rate compared with the placebo group 
suggesting a good compliance and adequate drug efficacy(59). Another similarity 
between the two studies is the limitation of not having the most up-to date 
follow-up records after the adjuvant therapy period, as a better understanding of 
the patients’ condition at later stages of the diagnosis and how they were 







Another randomized controlled study under the name of the OVERCOME trial, 
conducted by Bosch et al(60), was seeking to assess the efficacy of the ACE 
inhibitor enalapril and the beta-blocker carvedilol in the prevention of 
chemotherapy-induced LVSD in patients suffering from Haematological 
cancers(60). 90 patients of which 36 were recently diagnosed with acute 
leukaemia and 54 with malignant haemopathies between the ages of 18 and 70 
years old with normal LVEF were divided into a control and enalapril + 
carvedilol (taken together) groups. Both drugs were started simultaneously 
within at least 24 hours prior to the commencement of the first chemotherapy 
cycle. The primary outcome of this study was to observe changes in LVEF from 
baseline via echocardiography and cardiac magnetic resonance imaging 6 
months after randomisation. Unlike in PROTECT-TAYSIDE study TnI and BNP 
were measured before and within 12 and 24 hours after each cycle. This would 
have been a beneficial addition to the study as it would have allowed a closer 
understanding of whether cardiac damage had occurred in patients.  
As this is also a controlled trial, investigators had the benefit of adjusting and 
determining the dose administrated. As mentioned earlier, this is not a 
possibility with retrospective cohort studies as the study is already been done 
meaning only the cumulative doses of different drugs are available to analyse.  
The OVERCOME trial showed that concomitant treatment of enalapril and 
carvedilol studied may prevent LVSD in patients undergoing high doses of 
chemotherapy. Interestingly their use of imaging modalities (mentioned above). 
Although the study population of the OVERCOME trial had different malignancy 
compared to PROTECT-TAYSIDE’s patients, one similarity between the two 




Another similarity is that both the ACE inhibitor and beta-blocker used did not 
show any strong efficacy in patients with heart failure and preserved ejection 
fraction. Additionally, due to the different malignancies studied in the above trial,  
more pronounced effects were seen in patients diagnosed with acute leukaemia 
which is contrary to the weak signal seen in PROTECT-TAYSDIE analysis. The 
low number of patients in OVERCOME trial was a limiting factor as the value 
found between the effect of intervention on LVEF and the type of disease was 
limited.  
The results of this trial may have important clinical implications as a large 
number of human studies unlike animal studies have shown very small 
significance. However the observations made in the OVERCOME trial may 
prove valuable as millions of people are treated with cancer very year and a 
large number of them will develop cardiac damage thus the clinical relevance of 
combining an ACE inhibitor and a beta-blocker to prevent damage may prove 
valuable. To confirm this though larger studies are required. 
A study by Cardinale et al(43) viewed consecutive cancer patients undergoing 
high-dose chemotherapy for different cancer conditions including breast cancer 
with elevated TnI who underwent anthracycline therapy. On a randomized 1:1 
ratio the ACE inhibitor enalapril was given to one group while the other group 
was assigned for placebo over a two-year period(43). TnI concentration was 
measured before and after each cycle of chemotherapy, at randomisation, prior 
to the administration of enalapril (in the group who received it) and up to 12 
months after the first dose of enalapril. In ACE inhibitor group, enalapril was 
started 1 month after the completion of the last cycle of chemotherapy in order 
to achieve the patient’s stability clinically and the ACEI treatment continued for 




different clinical assessments including echocardiography to assess LVEF at 
baseline and up to 12 months after the end of chemotherapy  
 
on a 3 monthly period(43). Another similarity shared was the primary endpoint 
which was an absolute decrease of >10 percent units at rested LVEF 
associated with a decrease below the normal value of 50%.  
114 women were enrolled in the study of which all showed elevated TnI levels 
once high-dose chemotherapy had ended and of the 58 patients who were 
assigned to the control group, 25 individuals (43%) had a decrease in LVEF of 
>10% units from baseline associated with below normal limit of 50%. None of 
the patients in the ACE inhibitor group displayed any of the above reductions 
which was deemed to be a statistically significant difference (p<0.001). in 
addition to a reduced LVEF in control subjects the percentage of increased TnI 
was notable, indicating further cardiac damage due to inflammatory processes 
triggered by high doses of chemotherapy. This was evident by their Kaplan-
Meier analysis where the incidence of primary endpoint was lower in the ACE 
inhibitor group (p<0.001)(43).   
Unlike the analysis in PROTECT-TAYSIDE study, no CoX multivariate analysis 
was performed as there were no events that occurred in the ACE inhibitor 
group, thus the hazard ratio could not be computed and the test therefore was 
not applicable. good 
Cardinale et al(43) reported the importance of using ACE inhibitors as they have 
shown to be effective eradicators of free radicals as they exert antioxidant 
effects on anthracyline-induced cardiotoxicity. The antioxidant effects are also 




the end of chemotherapy, as they had a greater chance of reduction in LVEF in 
the long run, if left untreated.   
 
They concluded that an early treatment with enalapril seems to be effective in 
preventing cardiotoxicity and may help to improve cardiac outcome as their 
results showed subjects who received ACE inhibitors had a preserved left 
ventricular function when enalapril was used prophylactically, compared to the 
control group(43).  Unlike the OVERCOME study, Cadinale et al(43) administrated 
the ACE inhibitor studied prior to the start of high-dose chemotherapy and 
achieved a higher statistical power compared to OVERCOME. This may 
suggest that using an ACE inhibitor prophylactically could possibly have better 
cardioprotective outcomes.                                                                                                                                                             
All of the examples of different trials described above share the commonality of 
being conducted within 2 years, unlike the PROTECT-TAYSIDE study which 
was done over a ten-year period retrospectively. Looking at a data over a longer 
period of time gave the benefit of detecting any trend changes in the way breast 
cancer therapy is managed. As an example doxorubicin was used until 2005 
and due to its more cardiotoxic nature, epirubicin was used more commonly 
after that period. This remark would have not been possible to see if the study 
was conducted over a shorter period of time.  
There is a clear vision that human studies show a mixed variation of results with 
many showing poor statistical powers and some showing good outcomes as to 





This represents a clear indication that more studies on bigger scales are 
required to investigate the clinical outcomes perhaps separately than 
investigating the drug efficacy statistically.  
Looking at the literature it seems that different results and observations may be 
achieved if clinical effects/outcomes were compared separately from results 
achieved via statistical analysis. Taken the studies above together, along with 
other small scaled human studies, the doses of anthracycline containing 
chemotherapy regimens show a strong degree of association statistically, 
between the cumulative dose given and reduction in LVEF in the long term and 
not short term as ventricular-dysfunction seems to be a rare occurring event.  
As mentioned in section 5.4 cardiac damage and arrhythmias have been found 
to occur within 20 years after the treatment has been complete, thus close 
monitoring of patients is rather necessary to detect early signs of anthracycline-
induced cardiomyopathy. Endocrine changes occur at small scales over period 
of time, hence the long term it takes for heart failure to occur after the last dose 
of chemotherapy. Other conditions such as depression and other mental issues 
can further speed up the occurrence of heart failure as they affect the overall 
cardiovascular well being of the patient.  
With current medical practice several treatment strategies are used to prevent 
or reduce the impact of cardiac toxicity. Examples of these strategies include 
changing the chemotherapy schedule administered, limiting the cumulative 
dose of anthracycline administrated, changing the anthracycline agent to a 
different analogue, the use of antioxidants and iron chelators such as 
dexrazoxan and the stoppage of chemotherapy and restarting it again once LV 
recovery has been achieved. The last approach may help the LV to recover 




treatment has ended. This is why it would be a better practice if prevention was 
the main objective rather than cure. Having these treatment approaches 
unfortunately has the drawback of inadequate clinical success as any changes 
to the chemotherapeutic regimens can compromise clinical success.  
As mentioned previously, the hypothesis of the PROTECT-TAYSIDE study was 
that agents such as ACE inhibitors, Beta-blockers and Statins thought to have a 
positive role in reducing or preventing anthracycline-induced cardiotoxicity. 
However, they were not found to have a protective effect statistically.  
This may be due to the geographical location of the study not geographical 
location but too few numbers as the data was extracted in Tayside, Scotland 
which reduces the size of the study power as the data are too regional and 
perhaps if more data from other regions of the country was included, a higher 
power could have been achieved though, the limitation of this would be the 
amount of time and financial resources required to conduct a multi-regional 
study.  
Like any research studies, this project also had other limitations and since this 
study was a retrospective population-based cohort study which unlike clinical 
trial studies exposure to drugs or outcomes can not be controlled and instead 
these have to be extracted from patient’s records; this presents a problem as 
not all records are accurately written. This is further described below. Other 
challenges included limited access to CHEMOCARE and Wisdom database, as 
the databases were accessible from the oncology department, and the offices 
were available 2-3 days of the week only for data extraction which caused a 
longer period of data collection. The use of CHEMOCARE was limited to 
specific staff from the oncology ward who were not always available to help with 




data from the Wisdom data base. However when using Wisdom many patients 
had missing information such as covering letters which are created on the first 
patient visit to the oncologist and include a list of the patient’s other medications  
as well as a brief medical history. This often presented a challenge as even 
though some patients had their medications listed, the exact duration and dose 
of medication often were not included.  
4.1 AUDIT Discussion 
 
Data from the audit suggest that although patients receiving a combination 
therapy (anthracycline and trastuzumab) as adjuvant treatment are closely 
monitored, surveillance in those receiving anthracycline alone is low. The 
reason behind this discrepancy between the two groups does not seem to be 
clear, but may be due to the long-standing perception that damage caused by 
anthracycline-induced cardiotoxicity is permanent (type-1 cardiotoxicity) and 
that patients need only be treated when symptomatic. This could be attributed 
to older, less sensitive cardiac imaging modalities that could only detect cardiac 
dysfunction at a later stage of the disease, hence reducing the chances of 
recovery. However, recent work clearly documents the reversibility of this 
damage, and highlight the importance of early detection with more 
contemporary imaging techniques and prompt treatment of cardiotoxicity. The 
data suggests closer collaboration between oncologists and cardiologists is 
needed in raising awareness to this problem and improving long term overall 
outcomes of cancer patients. The data achieved from this audit will hopefully 
improve patient safety in clinical practice and more patients will undergo follow 
up assessments to detect cardiac complications early, as cancer therapy 





5 Concluding remarks 
 
Although novel anti-cancer drugs and treatment strategies have changed, 
breast cancer is now a survivable chronic condition. The success rate for 
survival has increased but this is usually at the cost of an increased risk of 
cardiac dysfunction due to chemotherapy-induced cardiotoxicity. Unfortunately 
to date the effects of cardioprotective drugs on chemotherapy-induced cardiac 
damage in human remains inconclusive thus larger scale trial studies with 
regards to the number of patients and duration of study (long-term 
observations) are required in order to find new treatment strategies.  
Long term follow-up of patients even after the completion of chemotherapy 
regimens are necessary as to date, this is the best approach to detect any early 
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